Skip to main content
SpringerLink
Log in

Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio in type 2 diabetes patients

  • Nephrology – Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

An Erratum to this article was published on 24 April 2012

Abstract

Background

Experimental studies have shown that adiponectin has antiproteinuric and nephroprotective effects. The purpose of the study was to assess the value of plasma adiponectin as a predictor of proteinuria in type 2 diabetes (T2D) patients.

Methods

In this one-year prospective follow-up study, we included T2D patients with positive visual test for microalbuminuria (Micral) and negative visual test for proteinuria. Exclusion criteria were: glomerular filtration ratio (GFR) < 30 ml/min, acute infection/inflammation, uncontrolled hypertension, and atherosclerotic complications. The main outcome measure was the change in urinary albumin/creatinine ratio (UACR) after 1 year follow-up (Δ UACR).

Results

Fifty-six patients (66% males) completed the study. Their initial mean UACR was 81.58 ± 26.42 mg/g and mean GFR was 81.15 ± 3.96 ml/min. At baseline, simple regression disclosed significant correlations between UACR and plasma adiponectin (r = 0.54, P = 0.00002) and GFR (r = −0.28, P = 0.03); in multiple regression analysis, plasma adiponectin remained the only predictor of UACR (P = 0.00007). Baseline plasma adiponectin was significantly correlated to body mass index (r = −0.28, P = 0.04), waist circumference (r = −0.27, P = 0.05), HDL cholesterol (r = 0.35, P = 0.01), and LDL cholesterol (r = 0.27, P = 0.04). Baseline plasma adiponectin significantly correlated in simple (r = −0.38, P = 0.004) and multiple regression (P = 0.04) to Δ UACR. When patients were divided according to Δ UACR in nonprogressors (Δ UACR < 0) and progressors (Δ UACR > 0), logistic regression showed that baseline GFR (OR = 1.04, CI95%: 1.00–1.09, P = 0.04) and plasma adiponectin (OR = 1.16, CI95%: 1.02–1.32, P = 0.02) were the only factors that predicted whether the patient would be a progressor or not.

Conclusion

In T2D patients, lower plasma adiponectin levels seem to be predictive of increased UACR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jansson PA, Pellmé F, Hammarstedt A et al (2003) A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J 17:1434–1440

    Article  PubMed  CAS  Google Scholar 

  2. Hopkins TA, Ouchi N, Shibata R, Walsh K (2007) Adiponectin actions in the cardiovascular system. Cardiovasc Res 74(1):11–18

    Article  PubMed  CAS  Google Scholar 

  3. Szmitko PE, Teoh H, Stewart DJ, Verma S (2007) Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 292(4):1655–1663

    Article  Google Scholar 

  4. Kadowaki T (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J Clin Invest 116:1784–1792

    Article  PubMed  CAS  Google Scholar 

  5. Nawrocki AR, Rajala MW, Tomas E et al (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J Biol Chem 281(5):2654–2660

    Article  PubMed  CAS  Google Scholar 

  6. Li S, Shin HJ, Ding EL, van Dam RM (2009) Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 302(2):179–188

    Article  PubMed  CAS  Google Scholar 

  7. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D (2005) Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol DialTransplant 20(1):129–134

    CAS  Google Scholar 

  8. Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD (2006) Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 91(1):129–135

    Article  PubMed  CAS  Google Scholar 

  9. Komaba H, Igaki N, Goto S et al (2006) Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 26(5):476–482

    Article  PubMed  CAS  Google Scholar 

  10. Norata GD, Baragetti I, Raselli S et al (2010) Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis 20(1):56–63

    Article  PubMed  CAS  Google Scholar 

  11. Barlovic DP, Zaletel J, Prezelj J (2009) Adipocytokines are associated with renal function in patients with normal range glomerular filtration rate and type 2 diabetes. Cytokine 46(1):142–145

    Article  PubMed  CAS  Google Scholar 

  12. Saraheimo M, Forsblom C, Thorn L et al (2005) Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28(6):1410–1414

    Article  PubMed  CAS  Google Scholar 

  13. Bakkaloglu SA, Soylemezoglu O, Buyan N et al (2005) High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse. Pediatr Nephrol 20(4):474–477

    Article  PubMed  Google Scholar 

  14. Shimotomai T, Kakei M, Narita T et al (2005) Enhanced urinary adiponectin excretion in IgA-nephropathy patients with proteinuria. Ren Fail 27(3):323–328

    PubMed  CAS  Google Scholar 

  15. Oguz Y, Yilmaz MI, Acikel C et al (2009) The relationship between adiponectin levels and degree of proteinuria in patients with nephrotic and nonnephrotic proteinuria. Ren Fail 31(1):29–35

    Article  PubMed  CAS  Google Scholar 

  16. Ohashi K, Iwatani H, Kihara S et al (2007) Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 27(9):1910–1917

    Article  PubMed  CAS  Google Scholar 

  17. Sharma K, Ramachandrarao S, Qiu G et al (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118(5):1645–1656

    PubMed  CAS  Google Scholar 

  18. Matsuzawa Y (2010) Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 86(2):131–141

    Article  PubMed  CAS  Google Scholar 

  19. Arita Y, Kihara S, Ouchi N et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83

    Article  PubMed  CAS  Google Scholar 

  20. Zoccali C, Mallamaci F, Tripepi G et al (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141

    Article  PubMed  CAS  Google Scholar 

  21. Ramos LF, Shintani A, Himmelfarb J, Ikizler TA (2009) Determinants of plasma adiponectin levels in nondiabetic subjects with moderate to severe chronic kidney disease. J Ren Nutr 19(3):197–203

    Article  PubMed  CAS  Google Scholar 

  22. Hotta K, Funahashi T, Arita Y et al (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20(6):1595–1599

    Article  PubMed  CAS  Google Scholar 

  23. Looker HC, Krakoff J, Funahashi T et al (2004) Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 89(8):4010–4017

    Article  PubMed  CAS  Google Scholar 

  24. Gottsäter A, Szelag B, Kangro M, Wroblewski M, Sundkvist G (2004) Plasma adiponectin and serum advanced glycated end-products increase and plasma lipid concentrations decrease with increasing duration of type 2 diabetes. Eur J Endocrinol 151(3):361–366

    Article  PubMed  Google Scholar 

  25. Lin J, Hu FB, Curhan G (2007) Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 30(2):239–244

    Article  PubMed  CAS  Google Scholar 

  26. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F (2007) Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the mild to moderate kidney disease study. Kidney Int 71(12):1279–1286

    Article  PubMed  CAS  Google Scholar 

  27. Jorsal A, Tarnow L, Frystyk J et al (2008) Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 74(5):649–654

    Article  PubMed  CAS  Google Scholar 

  28. Menon V, Li L, Wang X et al (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17(9):2599–2606

    Article  PubMed  CAS  Google Scholar 

  29. Zoccali C, Mallamaci F (2007) Adiponectin and renal disease progression: another epidemiologic conundrum? Kidney Int 71(12):1195–1197

    Article  PubMed  CAS  Google Scholar 

  30. Zoccali C, Mallamaci F (2011) Adiponectin and leptin in chronic kidney disease: causal factors or mere risk markers? J Ren Nutr 21(1):87–91

    Article  PubMed  CAS  Google Scholar 

  31. Stenvinkel P (2011) Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. J Ren Nutr 21(1):82–86

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was funded by CNCSIS Romania Idei 1167/2008 grant.

Author information

Authors and Affiliations

  1. Department of Nephrology, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, 3-5 Clinicilor Street, 400006, Cluj Napoca, Romania

    I. Kacso, A. Lenghel, D. Moldovan, C. Rusu & M. Gherman Caprioara

  2. Department of Informatics and Biostatistics, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, 6 Pasteur Street, 400349, Cluj Napoca, Romania

    C. I. Bondor

  3. Department of Diabetes and Nutrition, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, 2 Clinicilor Street, 400006, Cluj Napoca, Romania

    C. Nita & N. Hancu

  4. Department of Oncology, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, 34-36 Republicii Street, 400115, Cluj-Napoca, Romania

    G. Kacso

  5. University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj Napoca, Dornei 47 Street, 400171, Cluj Napoca, Romania

    G. Kacso

Authors
  1. I. Kacso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Lenghel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. I. Bondor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Moldovan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Rusu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Nita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Kacso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Hancu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Gherman Caprioara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Kacso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kacso, I., Lenghel, A., Bondor, C.I. et al. Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio in type 2 diabetes patients. Int Urol Nephrol 44, 1151–1157 (2012). https://doi.org/10.1007/s11255-011-0064-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-011-0064-1

Keywords

Search

Navigation